Nail-patella syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2614OMIM:161200Q87.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Nail-patella syndrome (NPS), also known as hereditary osteo-onychodysplasia (HOOD syndrome), Fong disease, or Turner-Kieser syndrome, is a rare genetic disorder caused by mutations in the LMX1B gene located on chromosome 9q34. This gene encodes a transcription factor critical for the development of the limbs, kidneys, and eyes. NPS is characterized by a classic tetrad of abnormalities affecting the nails, knees, elbows, and pelvis. Nail changes are the most consistent feature and typically include absent, hypoplastic, or dystrophic fingernails, most severely affecting the thumbnails and index fingernails. The patellae (kneecaps) are often small, irregularly shaped, or completely absent, leading to knee instability and recurrent dislocations. Skeletal manifestations also include iliac horns — bony projections from the posterior iliac bones that are virtually pathognomonic for the condition — as well as limited elbow extension, cubitus valgus, and radial head subluxation or dislocation. Beyond the musculoskeletal system, NPS can affect the kidneys, with approximately 30–50% of patients developing nephropathy characterized by proteinuria and, in a smaller percentage (roughly 5–10%), progression to end-stage renal disease. Ocular involvement includes open-angle glaucoma and ocular hypertension, which may develop at a younger age than in the general population. Some patients also experience peripheral neuropathy and vasomotor disturbances. There is currently no cure for nail-patella syndrome, and management is symptomatic and multidisciplinary. Orthopedic interventions may be needed for joint instability or skeletal deformities. Regular monitoring of kidney function (urinalysis and blood pressure) is essential, and nephropathy is managed with ACE inhibitors or angiotensin receptor blockers when proteinuria is detected. Ophthalmologic screening for glaucoma is recommended. Genetic counseling is important given the autosomal dominant inheritance pattern, with each affected individual having a 50% chance of passing the condition to their offspring. The clinical expression is highly variable, even within the same family.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal digit morphologyHP:0011297Decreased muscle massHP:0003199Abnormal iris pigmentationHP:0008034Equinovarus deformityHP:0008110Iliac hornsHP:0009780Abnormality of the elbowHP:0009811Abnormal gastrointestinal tract morphologyHP:0012718Fingernail dysplasiaHP:0100798
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Nail-patella syndrome.

View clinical trials →

No actively recruiting trials found for Nail-patella syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Nail-patella syndrome community →

No specialists are currently listed for Nail-patella syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Nail-patella syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Nail-patella syndromeForum →

No community posts yet. Be the first to share your experience with Nail-patella syndrome.

Start the conversation →

Latest news about Nail-patella syndrome

No recent news articles for Nail-patella syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Nail-patella syndrome

What is Nail-patella syndrome?

Nail-patella syndrome (NPS), also known as hereditary osteo-onychodysplasia (HOOD syndrome), Fong disease, or Turner-Kieser syndrome, is a rare genetic disorder caused by mutations in the LMX1B gene located on chromosome 9q34. This gene encodes a transcription factor critical for the development of the limbs, kidneys, and eyes. NPS is characterized by a classic tetrad of abnormalities affecting the nails, knees, elbows, and pelvis. Nail changes are the most consistent feature and typically include absent, hypoplastic, or dystrophic fingernails, most severely affecting the thumbnails and index

How is Nail-patella syndrome inherited?

Nail-patella syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Nail-patella syndrome typically begin?

Typical onset of Nail-patella syndrome is neonatal. Age of onset can vary across affected individuals.